EicOsis pioneers a novel approach to neuroinflammation and pain by targeting soluble epoxide hydrolase (sEH) inhibition, offering a safer, more effective alternative to traditional treatments. With funding from the Michael J. Fox Foundation, and strong preclinical and clinical data, including efficacy in natural disease models and completed Phase 1 trials, EicOsis is set to transform pain and neurodegenerative disease treatment.